MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section. About Profound Medical Corp. Profound is a ...

Prodeon Medical, Inc., a medical device company developing a minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia ...

Researchers shed light on the genes that could be linked to the high mortality rates of prostate cancer among men of African ...

VIJAYAWADA: Prashanth Hospital in Vijayawada introduced Resume Water Vapour Therapy for prostate problems, a first in the ...

Anticipated growth for ‘Saudi Arabia Benign Prostatic Hyperplasia Treatment Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising due to ...

Benign prostatic hyperplasia (BPH), also called prostate gland enlargement, is a common condition that older men can suffer ...

As with any new supplement, it's crucial to consult a healthcare provider before starting ProstaVive, particularly if you have pre-existing conditions, are on other medications, or are undergoing ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...

The study found that Focal One's treatment methods match up with the gold star standard of surgery, and improve quality of life outcomes.